Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

    On a vote by ballot, the following seven nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:     In addition to the election of all nominees listed as directors in the management information circular, datedMarch 23, 2021, Oncolytics...

SAN DIEGO, 10/05/2021 (informazione.news - comunicati stampa - scienza e tecnologia)

 

On a vote by ballot, the following seven nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:

 

 

In addition to the election of all nominees listed as directors in the management information circular, dated March 23 , 2021, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at seven and appointing auditors for the Corporation for the ensuing year.

For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at www.sedar.com. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies of pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg

Jon Patton
Director of IR & Communication
+1-858-886-7813
jpatton@oncolytics.ca

Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com